Bio-Rad Laboratories, Inc. (BIO-B) Comparison with companies in other sectors?

Bio-Rad Laboratories, Inc. has a share price of 26.54M. You can analyze Bio-Rad Laboratories, Inc. (BIO-B) competitors across different market sectors through stock heatmaps.

What are BIO-B's NET and operating margins?

Bio-Rad Laboratories, Inc. (BIO-B) operating margin is around 0.10, and net profit margin is approximately -0.88 as of the latest reports.

In what way does BIO-B's earnings per share (EPS) trend reflect its financial momentum?

Bio-Rad Laboratories, Inc. (BIO-B) EPS is -76.53 (If EPS value is positive, then “signals consistent profit growth” if Negative then “signals consistent loss”). This metric is also critical in assessing valuation metrics like the P/E ratio for Bio-Rad Laboratories, Inc. is -3.37, and the company’s ability to reinvest or distribute profits.

What does a high ROE mean for Bio-Rad Laboratories, Inc.?

A high ROE suggests efficient use of shareholder equity to generate profit. It often signals strong management and profitability.

How do I know if AAPL is overvalued or undervalued?

Check valuation ratios for Bio-Rad Laboratories, Inc. like P/E which is -3.23, P/B which is 1.08, and PEG which is 0.19. Compare them with sector averages to evaluate if the stock is priced fairly.

Bio-Rad Laboratories, Inc.

BIO-B•NYSE

Healthcare

Medical - Devices

$257.75

$7.67(3.07%)

Fundamental Analysis of Bio-Rad Laboratories, Inc. (BIO-B)

Comprehensive financial metrics and ratios analysis

EPS (TTM)

$-76.53

P/E Ratio

-3.37

ROE

-0.32%

Net Margin

-0.88%

Key Financial Metrices

Valuation Metrics

4 metrics

Market CapTotal market value of outstanding shares

$7.01B

Shares OutstandingTotal number of shares issued

$26.54M

Book Value/ShareNet worth per share

$239.05

Revenue/ShareAnnual revenue per share

$90.94

Profitability Metrics

6 metrics

EPS (TTM)Earnings per share trailing twelve months

$-76.53

Net MarginNet income as percentage of revenue

-87.68%

Operating MarginOperating income as percentage of revenue

9.71%

ROEReturn on shareholders' equity

-32.39%

ROAReturn on total assets

-23.39%

ROCEReturn on capital employed

2.74%

Cash Flow Metrics

3 metrics

Free Cash Flow/ShareCash generated per share after capex

$11.89

Cash/ShareCash and equivalents per share

$18.70

FCF YieldFree cash flow as percentage of market cap

4.74%

Dividend Metrics

2 metrics

Dividend/ShareAnnual dividend payment per share

Dividend YieldAnnual dividend as percentage of stock price

Financial Ratios Analysis data is not available for BIO-BFinancial Ratios Analysis details for BIO-B are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Sector Benchmarking data is not available for BIO-BSector Benchmarking details for BIO-B are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Understanding Fundamental Analysis for Bio-Rad Laboratories, Inc. Investment Decisions

What is Fundamental Analysis?

Fundamental analysis is a method used to assess the intrinsic value of Bio-Rad Laboratories, Inc.. Using financial reports, management structure, competitive position, and market environment, investors can determine whether the stock is undervalued or overvalued. This analysis helps investors like you make more informed investment decisions, taking into account Bio-Rad Laboratories, Inc.'s unique business strengths and challenges.

Key Financial Metrics for Bio-Rad Laboratories, Inc.

For Bio-Rad Laboratories, Inc., essential financial indicators include EPS -76.53, PE -3.37, and ROE -0.32. These key ratios reveal insights into Bio-Rad Laboratories, Inc.'s profitability, valuation, and operational health. Understanding these metrics enables you to compare Bio-Rad Laboratories, Inc. with its industry peers and decide whether it presents a viable investment opportunity.

Profitability and Operational Efficiency of Bio-Rad Laboratories, Inc.

Metrics like Net Margin -87.68% and ROA -23.39% shed light on how well Bio-Rad Laboratories, Inc. is generating profits. A high profitability ratio often indicates strong management and a solid business model, which are essential for long-term growth. These metrics are crucial in assessing whether Bio-Rad Laboratories, Inc. can sustain its operations and continue growing in the future.

Valuation and Market Position of Bio-Rad Laboratories, Inc.

Using ratios such as P/B Ratio 1.08 and PEG Ratio 0.19, investors can assess whether Bio-Rad Laboratories, Inc. is appropriately valued based on its financials and growth potential. These figures, combined with Bio-Rad Laboratories, Inc.'s market capitalization, give insight into its competitive positioning and investor expectations, helping you make informed decisions on pricing and value.

Financial Health and Risk Assessment for Bio-Rad Laboratories, Inc.

Financial health indicators, such as Debt/Equity Ratio 0.21 and Cash Flow $11.89, provide a snapshot of Bio-Rad Laboratories, Inc.'s ability to meet financial obligations and handle economic setbacks. A company with a strong balance sheet and solid cash flow, like Bio-Rad Laboratories, Inc., is more likely to weather financial storms, making it a safer investment.

Long-Term Investment Strategy for Bio-Rad Laboratories, Inc.

Investing in Bio-Rad Laboratories, Inc. based on fundamental analysis emphasizes long-term business growth rather than short-term market trends. Investors looking at Bio-Rad Laboratories, Inc. focus on its solid financial performance, industry standing, and competitive advantages, all of which suggest sustainable growth and the potential for steady returns over time.

Fundamental Analysis FAQ

;